Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
Abstract
Ensuring adherence to therapy is a challenge in chronic diseases, particularly in cancers such as chronic myeloid leukemia (CML), where there has been increased availability and use of oral formulations. A conceptual model of adherence was developed based on findings from a comprehensive literature review, to inform strategies for improving adherence to oral CML therapies. A complex interplay of factors (including clinical, psychological and behavioural) influence adherence to such therapies. Healthcare professionals have a key role in promoting and facilitating adherence and future strategies should place greater emphasis on understanding patient-level experiences in order to create personalized solutions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Interconnectivity between the WHO dimensions is an important aspect of medication adherence, supported by a number of conceptual frameworks but missing or not fully considered in others.
“A white rim surrounding the five dimensions of medication adherence serves to signify the interconnectivity between the dimensions, an important aspect of medication adherence supported by a number of conceptual frameworks11, 42, 66, 85 but were missing or not fully considered in others.50, 69, 115”
From An Adaptable Framework for Factors Contributing to Medication Adherence: Results from a Systematic Review of 102 Conceptual Frameworks (2021) · cites this paper as [66]
Cites
The theory of planned behavior
Ajzen, I. (1991) · Organizational Behavior and Human Decision Processes · doi:10.1016/0749-5978(91)90020-t · Cited by 90,587 · see citing works
(1985) · Medical Entomology and Zoology · Cited by 19,180 · see citing works
The Need for a New Medical Model: A Challenge for Biomedicine
Engel, G. L. (1977) · Science · doi:10.1126/science.847460 · Cited by 12,887 · see citing works
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,528 · see citing works
Adherence to Long-Term Therapies: Evidence for Action
Geest, S. D., & Sabate, E. J. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,274 · see citing works
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,473 · see citing works
Self-citationAdherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526 · see citing works
Physician Communication and Patient Adherence to Treatment
Haskard‐Zolnierek, K. B., & DiMatteo, M. R. (2009) · Medical Care · doi:10.1097/mlr.0b013e31819a5acc · Cited by 2,522 · see citing works
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220 · see citing works
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169 · see citing works
Harrison's Principles of Internal Medicine
Somberg, J. C. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000179344.69594.75 · Cited by 2,123 · see citing works
The consideration of future consequences: Weighing immediate and distant outcomes of behavior.
Strathman, A., Gleicher, F., Boninger, D. S., & Edwards, C. S. (1994) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.66.4.742 · Cited by 1,782 · see citing works
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H. M., Shah, N. P., Hochhaus, A., Cortes, J. E., Shah, S. A., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasqüini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,572 · see citing works
Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276 · see citing works
Self-citationHarrison's Principles of Internal Medicine 16th ed
Badiu, C. (2005) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2005.499 · Cited by 1,026 · see citing works
Patient preferences for oral versus intravenous palliative chemotherapy.
Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.110 · Cited by 917 · see citing works
Marín, D., Bazeos, A., Mahon, F., Eliasson, L., Milojković, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 911 · see citing works
The Need for a New Medical Model: A Challenge for Biomedicine
Engel, G. L. (2012) · Psychodynamic Psychiatry · doi:10.1521/pdps.2012.40.3.377 · Cited by 894 · see citing works
The Health Belief Model and prediction of dietary compliance: a field experiment.
Becker, M., Maiman, L. A., Kirscht, J. P., Haefner, D., & Drachman, R. (1977) · Journal of Health and Social Behavior · doi:10.2307/2955344 · Cited by 854 · see citing works
Kantarjian, H. M., Giles, F. J., Gattermann, N., Bhalla, K. N., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F. E., O’Brien, S. G., Litzow, M. R., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 740 · see citing works
Noens, L. A., van Lierde, M.-A., Bock, R. D., Verhoef, G. E. G., Zachée, P., Berneman, Z. N., Martiat, P., Mineur, P., Eygen, K. V., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 618 · see citing works
Deininger, M. W., O’Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M. D., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 615 · see citing works
Self-citationPicard, S., Titier, K., Étienne, G., Teilhet, E., Ducint, D., Bernard, M., Lassalle, R., Marit, G., Reiffers, J. J., Bégaud, B., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 610 · see citing works
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.9.652 · Cited by 585 · see citing works
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · see citing works
NCCN Task Force Report: Oral Chemotherapy
Weingart, S. N., Brown, E., Bach, P. B., Eng, K. J., Johnson, S. A., Kuzel, T. M., Langbaum, T. S., Leedy, R. D., Muller, R. J., Newcomer, L. N., et al. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.2003 · Cited by 438 · see citing works
Borner, M., Schöffski, P., de Wit, R., Caponigro, F., Comella, G., Sulkes, A., Greim, G., Peters, G. J., van der Born, K., Wanders, J., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00371-9 · Cited by 318 · see citing works
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271 · see citing works
Kantarjian, H. M., Talpaz, M., O'Brien, S. M., Jones, D. M., Giles, F. J., Garcia‐Manero, G., Faderl, S. H., Ravandi, F., Rios, M. B., Shan, J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004325 · Cited by 208 · see citing works
Ganesan, P., Sagar, T. G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., & Nandennavar, M. (2011) · American Journal of Hematology · doi:10.1002/ajh.22019 · Cited by 196 · see citing works
McHorney, C. A. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802619425 · Cited by 192 · see citing works
How well do clinicians estimate patients’ adherence to combination antiretroviral therapy?
Miller, L. G., Liu, H., Hays, R. D., Golin, C. E., Beck, C. K., Asch, S. M., Ma, Y., Kaplan, A. H., & Wenger, N. S. (2002) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2002.09004.x · Cited by 188 · see citing works
Eliasson, L., Clifford, S., Barber, N., & Marín, D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.10.017 · Cited by 188 · see citing works
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Wei, G., Rafiyath, S. M., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-47 · Cited by 169 · see citing works
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
Bixby, D. L., & Talpaz, M. (2010) · Leukemia · doi:10.1038/leu.2010.238 · Cited by 162 · see citing works
Kantaijian, H. (2007) · Blood · Cited by 143 · see citing works
Current and emerging treatment options in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., Giles, F. J., O'Brien, S. M., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22661 · Cited by 134 · see citing works
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903396469 · Cited by 126 · see citing works
Self-citationCortes, J. E., Egorin, M. J., Guilhot, F., Molimard, M., & Mahon, F. (2009) · Leukemia · doi:10.1038/leu.2009.88 · Cited by 110 · see citing works
Self-citationOral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety
Halfdanarson, T. R., & Jatoi, A. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0103-6 · Cited by 90 · see citing works
Facilitation of Patient Involvement in Care: Development and Validation of a Scale
Martin, L. R., Matteo, M. R. D., & Lepper, H. S. (2001) · Behavioral Medicine · doi:10.1080/08964280109595777 · Cited by 89 · see citing works
Wu, E. Q., Guérin, A., Yu, A. P., Bollu, V. K., Guo, A. X., & Griffin, J. D. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.533648 · Cited by 66 · see citing works
Tsang, J., Rudychev, I., & Pescatore, S. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.6119 · Cited by 64 · see citing works
Perspectives on Adherence and Persistence With Oral Medications for Cancer Treatment
Hohneker, J. A., Shah-Mehta, S., & Brandt, P. S. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2010.000076 · Cited by 43 · see citing works
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
Breccia, M., Efficace, F., & Alimena, G. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.10.018 · Cited by 40 · see citing works
StCharles, M. E., Bollu, V. K., Hornyak, E., Coombs, J. H., Blanchette, C. M., & DeAngelo, D. J. (2009) · Blood · doi:10.1182/blood.v114.22.2209.2209 · Cited by 39 · see citing works
Self-citationCompliance and persistency with imatinib
Feng, W., Henk, H. J., Thomas, S. M., Baladi, J., Hatfield, A. K., Goldberg, G. A., & Cortes, J. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.6038 · Cited by 31 · see citing works
Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia
Marín, D. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.003 · Cited by 25 · see citing works
Ibrahim, A. R., Milojković, D., Bua, M., Khorshad, J. S., Szydlo, R., Eliasson, L., Foroni, L., Reid, A. G., de Lavallade, H., Rezvani, K., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3414.3414 · Cited by 22 · see citing works
Bazeos, A., Khorashad, J. S., Mahon, F., Eliasson, L., Milojković, D., Bua, M., Apperley, J. F., Szydlo, R., Kozlowski, K., Paliompeis, C., et al. (2009) · Blood · doi:10.1182/blood.v114.22.3290.3290 · Cited by 16 · see citing works
Kiguchi, T., Tauchi, T., Ito, Y., Miyazawa, K., Kimura, Y., & Ohyashiki, K. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.04.018 · Cited by 14 · see citing works
Halpern, R., Barghout, V. E., Mody‐Patel, N., & Williams, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.6598 · Cited by 11 · see citing works
Yood, M. U., Oliveria, S. A., Hirji, I., Cziraky, M. J., & Davis, C. (2010) · Blood · doi:10.1182/blood.v116.21.1235.1235 · Cited by 10 · see citing works
Cartier, A., & Henneberger, P. K. (2013) · CRC Press eBooks · doi:10.1201/b15116-15 · Cited by 8 · see citing works
Halpern, R., Barghout, V. E., & Williams, D. (2007) · Blood · doi:10.1182/blood.v110.11.5159.5159 · Cited by 8 · see citing works
Wu, E. Q., Bollu, V. K., Guo, A. X., Guérin, A., Yu, A. P., Sirulnik, A., & Griffin, J. D. (2009) · Blood · doi:10.1182/blood.v114.22.4270.4270 · Cited by 8 · see citing works
Fogliatto, L., Capra, M., Shaan, M., Fassina, K., Fernandes, M. S., Schilling, M. A., Almeida, D., Nene, M., Hellwig, T., Nachtigal, G. C., et al. (2010) · Blood · doi:10.1182/blood.v116.21.2296.2296 · Cited by 5 · see citing works
Johnson, C. N., Cowan, L. N., Gorospe, G., & Ailawadhi, S. (2010) · Blood · doi:10.1182/blood.v116.21.4481.4481 · Cited by 5 · see citing works
Gurion, R., Vidal, L., Gafter-Gvili, A., Belnik, Y., Yeshurun, M., Raanani, P., & Shpilberg, O. (2010) · Haematologica · doi:10.3324/haematol.2009.020420 · Cited by 4 · see citing works
Guérin, A., Bollu, V. K., Guo, A. X., Stepner, M., Griffin, J. D., & Wu, E. Q. (2011) · Blood · doi:10.1182/blood.v118.21.2754.2754 · Cited by 4 · see citing works
Adherence to Imatinib Mesylate Treatment: Two Years Follow up
Doti, C. A., Stemmelin, G. R., Moiraghi, E. B., Flores, M. G., Garcia, J., Murro, H., & Bullorsky, E. O. (2008) · Blood · doi:10.1182/blood.v112.11.4267.4267 · Cited by 4 · see citing works
van Lierde, M.-A., Serra, F., Rop, L. D., Strobbe, E., MacDonald, K., Vancayzeele, S., Geest, S. D., Letvak, L. A., Albrecht, T., & Abraham, I. L. (2007) · Blood · doi:10.1182/blood.v110.11.5163.5163 · Cited by 3 · see citing works
van Lierde, M.-A., Rop, L. D., Serra, F., Strobbe, E., MacDonald, K., Vancayzeele, S., Geest, S. D., Letvak, L. A., Albrecht, T., & Abraham, I. L. (2007) · Blood · doi:10.1182/blood.v110.11.5164.5164 · Cited by 3 · see citing works
Almeida, M. H., Pagnano, K. B. B., Souza, H., MIRANDA, E. C. M., & Souza, C. A. D. (2010) · Blood · doi:10.1182/blood.v116.21.4477.4477 · Cited by 2 · see citing works
Noens, L. A., van Lierde, M.-A., Bock, R. D., Verhoef, G. E. G., Zachée, P., Berneman, Z. N., Martiat, P., Mineur, P., Eygen, K. V., MacDonald, K., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2379.2379 · Cited by 2 · see citing works
Wu, E. Q., Feng, W., Johnson, S. J., Beaulieu, N. D., Crémieux, P., & Cortes, J. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.17514 · Cited by 2 · see citing works
Flagged first, then by citations
4 of the 70 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, É., Paci, A., Beijnen, J. H., Levêque, D., Veal, G. J., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 299 · see citing works
Peh, K. Q. E., Kwan, Y. H., Goh, H., Ramchandani, H., Phang, J. K., Lim, Z. Y., Loh, D. H. F., Østbye, T., Blalock, D. V., Yoon, S., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06648-1 · Cited by 151 · see citing works
Adherence to targeted oral anticancer medications.
Geynisman, D. M., & Wickersham, K. E. (2013) · PubMed · Cited by 92 · see citing works
Noens, L. A., Hensen, M., Kucmin-Bemelmans, I., Löfgren, C., Gilloteau, I., & Vrijens, B. (2014) · Haematologica · doi:10.3324/haematol.2012.082511 · Cited by 81 · see citing works
Hall, A. E., Paul, C. L., Bryant, J., Lynagh, M., Rowlings, P., Enjeti, A. K., & Small, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.025 · Cited by 77 · see citing works
Bouwman, L., Eeltink, C., Visser, O. J., Janssen, J. J. W. M., & Maaskant, J. M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3735-1 · Cited by 75 · see citing works
Kekäle, M., Airaksinen, M., Porkka, K., Talvensaari, K. K., & Koskenvesa, P. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s70712 · Cited by 49 · see citing works
Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
Rychter, A., Jerzmanowski, P., Hołub, A., Specht-Szwoch, Z., Kalinowska, V., Tęgowska, U., Seferyńska, I., Kołkowska‐Leśniak, A., Lech‐Marańda, E., & Góra‐Tybor, J. (2017) · Medical Oncology · doi:10.1007/s12032-017-0958-6 · Cited by 41 · see citing works
Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
Chen, L.-C., Chen, T.-C., Huang, Y.-B., & Chang, C.-S. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9867-8 · Cited by 39 · see citing works
Irwin, M., & Johnson, L. A. (2015) · Clinical journal of oncology nursing · doi:10.1188/15.s1.cjon.6-30 · Cited by 39 · see citing works
Shen, C., Zhao, B., Liu, L., & Shih, Y. T. (2017) · Cancer · doi:10.1002/cncr.31050 · Cited by 38 · see citing works
Almeida, M. H., Pagnano, K. B. B., Vigorito, A. C., Lorand-Metze, I. G. H., & Souza, C. A. D. (2013) · Acta Haematologica · doi:10.1159/000345722 · Cited by 38 · see citing works
Barthélémy, P., Asmane, I., Meyer, N., Duclos, B., Serra, S., Dourthe, L.-M., Amé, S., Litique, V., Giron, C., Goldbarg, V., et al. (2014) · Oncology · doi:10.1159/000366226 · Cited by 35 · see citing works
Kavookjian, J., & Wittayanukorn, S. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.08.006 · Cited by 31 · see citing works
Hewison, A., Atkin, K. M., McCaughan, D., Roman, E., Smith, A. G., Smith, G., & Howell, D. A. (2020) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2020.101730 · Cited by 28 · see citing works
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
Nasser, A., Hussein, A. K., Chamba, C. C., Yonazi, M., Mushi, R., Schuh, A., & Luzzatto, L. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002973 · Cited by 26 · see citing works
Boons, C. C. L. M., Harbers, L., Timmers, L., de Jong, J., Swart, E. L., Hendrikse, N. H., Janssen, J. J. W. M., & Hugtenburg, J. G. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13155 · Cited by 24 · see citing works
mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice
Pennell, N. A., Dicker, A. P., Tran, C. N., Jim, H., Schwartz, D. L., & Stepanski, E. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_176093 · Cited by 26 · see citing works
Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
Chen, T., Chen, L., Huang, Y., & Chang, C. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9876-7 · Cited by 23 · see citing works
The impact of socio‐economic factors on treatment choice and mortality in chronic myeloid leukaemia
Larfors, G., Sandin, F., Richter, J., Själander, A., Stenke, L., Lambe, M. P., & Höglund, M. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12845 · Cited by 23 · see citing works
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients
Barratt, D. T., Cox, H. K., Menelaou, A., Yeung, D. T. O., White, D. L., Hughes, T. P., & Somogyi, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0494-0 · Cited by 23 · see citing works
Gassmann, C., Kolbe, N., & Brenner, A. (2016) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2016.06.001 · Cited by 21 · see citing works
Tan, B. K., Bee, P. C., Chua, S. S., & Chen, L. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s269355 · Cited by 20 · see citing works
Escudero-Ortíz, V., Domínguez-Leñero, V., Catalán-Latorre, A., Rebollo-Liceaga, J., & Sureda, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061216 · Cited by 18 · see citing works
Tan, B. K., Tan, S. B., Chen, L., Chang, K. M., Chua, S. S., Balashanker, S., Begum, H. N., Edmund, S. C., & Bee, P. C. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s132894 · Cited by 18 · see citing works
Leader, A., Benyamini, N., Gafter‐Gvili, A., Dreyer, J., Calvarysky, B., Amitai, A., Yarchovsky-Dolberg, O., Sharf, G., Tousset, E., Caspi, O., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.026 · Cited by 17 · see citing works
Breccia, M., Efficace, F., & Alimena, G. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.032 · Cited by 17 · see citing works
Bandiera, C., Locatelli, I., Courlet, P., Cardoso, E., Zaman, K., Stravodimou, A., Dolcan, A., Sarivalasis, A., Zurcher, J.-P., Aedo-Lopez, V., et al. (2023) · Cancers · doi:10.3390/cancers15010316 · Cited by 18 · see citing works
Cheng, F., Cui, Z., Li, Q., Wang, L., & Li, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110847 · Cited by 16 · see citing works
Treating Chronic Myeloid Leukemia
Simoneau, C.-A. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.e13-e20 · Cited by 16 · see citing works
Adherence-Related Issues in Adolescents and Young Adults with Hematological Disorders
Leader, A., & Raanani, P. (2014) · Acta Haematologica · doi:10.1159/000360197 · Cited by 14 · see citing works
Lim, Y. M., Eng, W. L., & Chan, H. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.7.1925 · Cited by 13 · see citing works
Muzellec, L., Bourien, H., & Edeline, J. (2021) · Cancers · doi:10.3390/cancers14010179 · Cited by 12 · see citing works
Patel, K., Sudhir, V. S., Kabadi, S., Huang, J., Porwal, S., Thakkar, K., & Pagel, J. M. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219827637 · Cited by 10 · see citing works
Dang, T. H., Wickramasinghe, N., Jayaraman, P. P., Burbury, K., Alexander, M., Whitechurch, A., Dyer, M., Quinn, S., Forkan, A. R. M., & Schofield, P. (2025) · JMIR Formative Research · doi:10.2196/65302 · Cited by 9 · see citing works
Clark, S. E., Marcum, Z. A., Radich, J. P., & Bansal, A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220970616 · Cited by 9 · see citing works
Lea, C. S., Bohra, S., Moore, T., Passwater, C., & Liles, D. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3935-z · Cited by 9 · see citing works
Boons, C. C. L. M., Swart, E. L., Timmers, L., van de Ven, P. M., Janssen, J. J. W. M., & Hugtenburg, J. G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-247 · Cited by 8 · see citing works
Tan, B. K., Chua, S. S., Chen, L., Chang, K. M., Balashanker, S., & Bee, P. C. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220964539 · Cited by 8 · see citing works
Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
Alves, A. R., Lima, W. G., Nagai, M. M., Rodrigues, J. P. V., & Ayres, L. R. (2016) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502016000400001 · Cited by 7 · see citing works
Lee, P. M., Chang, C. T., & Yusoff, Z. M. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01070-9 · Cited by 7 · see citing works
Factors Influencing Medication Adherence to Oral Anticancer Drugs
Lee, Y. H., & Jeong, I. S. (2013) · Asian Oncology Nursing · doi:10.5388/aon.2013.13.4.201 · Cited by 6 · see citing works
Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors.
Hefner, J., Csef, E.-J., & Kunzmann, V. (2016) · Oncology Nursing Forum · doi:10.1188/16.onf.190-197 · Cited by 7 · see citing works
Morgan, J., DeBoer, R. J., Bigirimana, J. B., Nguyen, C., Ruhangaza, D., Paciorek, A. T., Mugabo, F., Villaverde, C., Nsabimana, N., Bihizimana, P., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00131 · Cited by 6 · see citing works
Insights on practice variations in the management of lymphoma and leukemia
Loberiza, F. R., Cannon, A. C., Cannon, A. J., & Bierman, P. J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.881480 · Cited by 6 · see citing works
Exploring perceptions and experiences of oral chemotherapy in people with cancer
Costa, A., & McGraw, C. (2018) · Cancer Nursing Practice · doi:10.7748/cnp.2018.e1464 · Cited by 4 · see citing works
Leader, A., Gafter‐Gvili, A., Benyamini, N., Dreyer, J., Calvarysky, B., Amitai, A., Yarchovsky-Dolberg, O., Sharf, G., Tousset, E., Caspi, O., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.007 · Cited by 4 · see citing works
Evaluation of patient adherence with oral anticancer agents
Kazaz, S. N., & Yıldırım, A. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_2238_22 · Cited by 3 · see citing works
How to report adherence to treatment as clinically relevant data—making a case of CML and TKI
Okumura, L. M. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3809-2 · Cited by 3 · see citing works
Sticking to the script: Breast cancer patients’ decision making regarding oral endocrine therapy
Wheeler, S. B., Roberts, M. C., Waters, A. R., Bloom, D. L., Peppercorn, J. M., Golin, C. E., & Reeder-Hayes, K. E. (2024) · Patient Education and Counseling · doi:10.1016/j.pec.2024.108349 · Cited by 2 · see citing works
McKay, R. R., Mills, H., Werner, L. L., Choudhury, A. D., Choueiri, T. K., Jacobus, S. J., Pace, A. F., Polacek, L. C., Pomerantz, M. M., Prisby, J., et al. (2018) · Journal of Medical Internet Research · doi:10.2196/12044 · Cited by 2 · see citing works
Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs
Zackon, A. Y. L., Ayers, A. A., Yeager, K. A., Somma, M. L., Friedberg, J. W., Flowers, C. R., & Nastoupil, L. J. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1594217 · Cited by 2 · see citing works
Gendermedizin: „Wir stehen erst am Anfang“
Keiner, D. (2017) · Deutsches Ärzteblatt · doi:10.3238/personko/2017.02.03.01
The Case for Digital Pill Use in Clinical Trials
Klein, G. L. (2021) · Clinical Trials and Practice – Open Journal · doi:10.17140/ctpoj-4-120
Patient Adherence to Oral Anticancer AgentsPreprint
Kazaz, S. N., & Yıldırım, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1417121/v1
Arias-Núñez, D., Chavarría-Víquez, C., & Morúa, M. S. Q. (2023) · Pharmaceutical care España · doi:10.60103/phc.v25i5.821
Sepassi, A., & Fendrick, A. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-02192
Costantini, M., Borsotti, M. T., Deleo, M., Mogos, I., & Nepoti, G. (2026) · Dissertation Nursing · doi:10.54103/dn/30640
- Authors
- Gater, A., Heron, L., Abetz-Webb, L., Coombs, J., Simmons, J., Guilhot, F., & Rea, D.
- Affiliations
- Adelphi Group (United Kingdom) (GB)
- Novartis (United States) (US)
- Inserm (FR)
- Corresponding author
- Gater, Adam
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 36
- Issue
- 7
- Pages
- 817-825
- ISSN
- 0145-2126 (ISSN-L)
- OpenAlex
- W2053873258
- Cited by
- 59
- References
- 70
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 2 · 2018: 6 · 2017: 8 · 2016: 5 · 2015: 2 · 2014: 8 · 2013: 6 · 2012: 2
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacy and Medical Practices
- Keywords
- medication adherence, chronic myeloid leukemia, tyrosine kinase inhibitors, oral anticancer therapy, psychological factors, behavioral factors, health professionals' role, patient experience
- MeSH terms
- Assessment of Medication Adherence, Administration, Oral, Antineoplastic Agents, Clinical Trials as Topic, Humans, Models, Biological, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Monitoring, Patient Satisfaction, Protein Kinase Inhibitors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
